ArticleExperimental and therapeutic medicine2020
LINC00210 plays oncogenic roles in non-small cell lung cancer by sponging microRNA-328-5p.
Article in Experimental and therapeutic medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- Regulatory roles of noncoding RNAs in intervertebral disc degeneration as potential therapeutic targets (Review).Experimental and therapeutic medicine · 2023Review
- miR-328-5p Induces Human Intervertebral Disc Degeneration by Targeting WWP2.Oxidative medicine and cellular longevity · 2022Article
- LncRNA LINC00210 regulated radiosensitivity of osteosarcoma cells via miR-342-3p/GFRA1 axis.Journal of clinical laboratory analysis · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long noncoding RNA (lncRNA) has an important role in regulating non-small cell lung cancer (NSCLC) progression. The present study aimed to investigate the effect of LINC00210 in NSCLC progression in order to provide a novel treatment target for patients with NSCLC. A total of 39 NSCLC patients were obtained and divided into LINC00210 high expression and low expression groups. Subsequently, the 5-year survival rate from this patient cohort was analyzed. The SK-MES-1 and A549 NSCLC and the human 16-HBE bronchial epithelial cell lines were utilized to investigate expression level of LIN00210. A549 cells were used to investigate cell proliferation, migration and invasive abilities using Cell Counting kit 8, Transwell and Matrigel assays, respectively. In addition, the luciferase reporter gene assay was performed to investigate the potential target of LINC00210. Reverse transcription-quantitative PCR was used to determine LINC00210 and microRNA (miR)-328-5p expression levels in NSCLC tissues and tumor cell lines (SK-MES-1 and A549). The results demonstrated that LINC00210 was upregulated in NSCLC tissues and cell lines compared with that in normal tissues and 16-HBE cells, and that LINC00210 expression was associated with a poor prognosis in patients with NSCLC (P<0.05). Furthermore, A549 cell transfection with small interfering (si)LINC00210#1 and siLINC00210#2 induced a significant decrease in cell proliferation, and migratory and invasive abilities compared with that in the control groups (P<0.05). In addition, miR-328-5p overexpression was stimulated by knockdown of LINC00210. Furthermore, A549 cells transfected with siLINC00210#1 and miR-328-5p inhibitor exhibited a significant increase in cell proliferation, and migratory and invasive ability compared with that in A549 cells transfected with siLINC00210#1. These findings suggest that LINC00210 may serve as an oncogenic role in NSCLC by sponging miR-328-5p.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.